PMID- 34941188
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20231213
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 51
DP  - 2021 Dec 23
TI  - Increased expression of interleukin-22 and its receptor is relevant to poor 
      prognosis in laryngeal squamous cell carcinoma: A case control trial.
PG  - e28419
LID - 10.1097/MD.0000000000028419 [doi]
LID - e28419
AB  - To detect the expression of interlerukin-22 (IL-22) and associated genes and to 
      evaluate their relationship with clinicopathological features and prognosis in 
      laryngeal squamous cell carcinoma (LSCC).The expression of IL-22 and associated 
      genes were evaluated by immunohistochemistry and real time polymerase chain 
      reaction in LSCC tissues from 30 patients and adjacent non-tumor tissues. A 
      statistical analysis was implemented to assess the relationship among levels of 
      expression, clinicopathological factors, and overall survival.The expression of 
      IL-22 and interleukin 22 receptor 1 (IL-22R1) was mainly located in the 
      cytoplasm, and the expression of LSCC was significantly higher than in controls. 
      The expression of aryl hydrocarbon receptor and signal transducer and activator 
      of transcription 3 distributed in the cell nucleus, which was significantly 
      higher in LSCC than in controls. The expression of IL-22 and IL-22R1 was 
      associated with metastasis of lymph node and clinical stage of LSCC. Overall 
      survival of LSCC was significantly poorer with higher expression of IL-22 and 
      IL-22R1 than in those with lower expression.The present research indicated that 
      the increased level of IL-22 and IL-22R1 may be related to the pathogenesis and 
      prognosis of LSCC. IL-22 may be the important biomarker, which need further 
      research.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Ji, Wenjun
AU  - Ji W
AD  - Department of Otorhinolaryngology & Head and Neck Surgery, The People's Hospital 
      of Su Zhou New District, Su Zhou, China.
FAU - Li, Jing
AU  - Li J
FAU - Wang, Xin
AU  - Wang X
AUID- ORCID: 0000-0001-8828-7007
FAU - Gao, Dongsheng
AU  - Gao D
FAU - Zhang, Tiantian
AU  - Zhang T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IL21R protein, human)
RN  - 0 (Interleukin-21 Receptor alpha Subunit)
RN  - 0 (Interleukins)
RN  - 0 (Receptors, Interleukin)
RN  - 0 (interleukin-22 receptor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Squamous Cell/metabolism/*mortality/pathology
MH  - Case-Control Studies
MH  - Female
MH  - *Head and Neck Neoplasms/mortality/pathology
MH  - Humans
MH  - Interleukin-21 Receptor alpha Subunit
MH  - Interleukins/*genetics
MH  - Laryngeal Neoplasms/metabolism/*mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptors, Interleukin/*genetics
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Interleukin-22
PMC - PMC8702255
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/12/24 06:00
MHDA- 2022/02/17 06:00
PMCR- 2021/12/23
CRDT- 2021/12/23 14:07
PHST- 2021/07/22 00:00 [received]
PHST- 2021/12/03 00:00 [accepted]
PHST- 2021/12/23 14:07 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
PHST- 2021/12/23 00:00 [pmc-release]
AID - 00005792-202112230-00164 [pii]
AID - MD-D-21-05194 [pii]
AID - 10.1097/MD.0000000000028419 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Dec 23;100(51):e28419. doi: 
      10.1097/MD.0000000000028419.